ScreenerHero

IMA ImageneBio, Inc.

NAS · US · Healthcare · Biotechnology · inmagenebio.com
4.610USD+0.22%Mkt Cap: 52.33M $P/E: —

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap52.33M USD
Enterprise Value-82.02M USD
Revenue (TTM)0 USD
Gross Profit0 USD
Net Income (TTM)-45.35M USD
Revenue/Share0.00 USD
Last Price4.610 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees18
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.07
PEG—
EV/EBITDA1.41
EV/Revenue—
P/SInfinity
P/B0.37
EPS (TTM)-4.00
EPS (Forward)-4.31
52W Range
3.94013% of range9.100
52W High9.100 USD
52W Low3.940 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-5668.63%
ROE-34.06%
ROA-29.64%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-47.84M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-44.36%
Net Debt-134.24M USD
Net Debt/EBITDA2.30
Balance Sheet
Debt/Equity0.02
Current Ratio21.47
Quick Ratio20.71
Book Value/Sh12.60 USD
Cash/Share11.99 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateJul 28, 2025
Analyst Consensus
Rating—
Target (Mean)18.00 USD
Upside (mean)+290.5%
Target Range2.000 USD – 28.00 USD
2.000+290.5% to mean28.00
# Analysts3
Ownership
Shares Out.11.35M
Float5.83M
Insiders16.19%
Institutions54.59%
Short Interest
Short Ratio2.5d
Short % Float0.31%
Short % Out.0.30%
Shares Short34.60K
Short (prev mo.)49.30K
Technical
SMA 505.249 (-12.2%)
SMA 2005.851 (-21.2%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)13.83K
Avg Vol (10d)7.85K
Technical Indicators
RSI (14)35.6
MACD-0.1934
MACD Signal-0.2083
MACD Hist.+0.0149
BB Upper5.145 USD
BB Middle4.786 USD
BB Lower4.427 USD
BB Width15.01%
ATR (14)0.2028 USD
Vol Ratio (20d)0.13x